Trials / Terminated
TerminatedNCT02429895
A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197
A Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197 Phase 2 Randomized Controlled Trial (RCT)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 168 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 2, Multicenter, Open-Label Extension (OLE) Study with ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197 Phase 2 Randomized Controlled Trial (RCT).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-122 | Injection |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2016-05-01
- Completion
- 2016-05-01
- First posted
- 2015-04-29
- Last updated
- 2016-06-17
Locations
36 sites across 10 countries: Australia, Bulgaria, Czechia, Germany, Hungary, Latvia, New Zealand, Poland, Romania, Spain
Source: ClinicalTrials.gov record NCT02429895. Inclusion in this directory is not an endorsement.